Quantitative assessment of barriers to the clinical development and adoption of cellular therapies: A pilot study
Year: 2014
Type: article
Study design: Observational Study
Abstract: There has been a large increase in basic science activity in cell therapy and a growing portfolio of cell therapy trials. However, the number of industry products available for widespread clinical use does not match this magnitude of activity. We hypothesize that the paucity of engagement with the clinical community is a key contributor to the lack of commercially successful cell therapy products. To investigate this, we launched a pilot study to survey clinicians from five specialities and to determine what they believe to be the most significant barriers to cellular therapy clinical development and adoption. Our study shows that the main concerns among this group are cost-effectiveness, efficacy, reimbursement, and regulation. Addressing these concerns can best be achieved by ensuring that future clinical trials are conducted to adequately answer the questions of both regulators and the broader clinical community.
Source: Journal of Tissue Engineering
Authors: Benjamin M Davies, Sarah Rikabi, Anna French, Rafael Pinedo-Villanueva, Mark E Morrey, Karolina Wartolowska, Andrew Judge, Robert E MacLaren, Anthony Mathur, David J Williams, Ivan Wall, Martin Birchall, Brock Reeve, Anthony Atala, Richard W Barker, Zhanfeng Cui, Dominic Furniss, Kim Bure, Evan Y Snyder, Jeffrey M Karp, Andrew Price, Andrew Carr, David A Brindley
Institutions: University of Oxford, Southampton General Hospital, MRC Lifecourse Epidemiology Unit, Mayo Clinic, Queen Mary University of London, Barts Health NHS Trust, London Chest Hospital, William Harvey Research Institute, Loughborough University, University College London, Dankook University, Harvard University, Harvard Stem Cell Institute, Wake Forest University Health Sciences, Wake Forest University, Sartorius (Germany), Sanford Burnham Prebys Medical Discovery Institute, University of California San Diego, Sanford Consortium for Regenerative Medicine, Brigham and Women's Hospital, Harvard–MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, UCL School of Pharmacy
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,519
Award: G2838808439
OpenAlex ID: W2126523804